BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells

Denosumab, a monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), might be a novel preventative therapy for BRCA1-mutation carriers at high risk of developing breast cancer. Beyond its well-recognized bone-targeted activity impeding osteoclastogenesis, denosumab has bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuyàs, Elisabet, Corominas-Faja, Bruna, Muñoz-San María, Martín, Martin-Castillo, Begoña, Lupu, Ruth, Brunet, Joan, Bosch-Barrera, Joaquim, Menendez, Javier A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471031/
https://www.ncbi.nlm.nih.gov/pubmed/28388533
http://dx.doi.org/10.18632/oncotarget.16558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471031/
https://www.ncbi.nlm.nih.gov/pubmed/28388533
http://dx.doi.org/10.18632/oncotarget.16558

Ejemplares similares